Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lovaza for TBI Recovery
NCT02990091Phase 2Withdrawn
- Sponsor
- University of Pennsylvania
- Start
- Jan 2017
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eicosapentaenoic acid + docosahexaenoic acid in traumatic brain injury (TBI) (4 arms), sponsored by University of Pennsylvania. Primary endpoint: Blood levels of synaptamide, 17-hydroxy-DHA, and D-series resolvins at 14 days. Planned start Jan 2017; status: withdrawn.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT02990091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02990091.